The MarketWatch News Department was not involved in the creation of this content. -- Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical ...
Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore complementary immuno-oncology mechanisms in extensive‑stage small ...
DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in ...
Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ...
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore complementary immuno-oncology mechanisms in extensive‑stage small ...
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, announced a clinical trial collaboration with BioNTech to evaluate a novel immuno-oncology combination in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results